The results of the current study confirmed former clinical associations with tumor mutational status, but also differed from the observations in stage IV melanoma concerning the role of BRAF or NRAS mutations as a prognostic marker following complete surgical resection of the metastatic regional lymph nodes. The gene discussed is BRAF; the disease is neoplasm.